Beiersdorf, DE0005200000

DZ Bank cuts fair value for Beiersdorf stock to EUR 74.00

Published on 10/05/2026 at 10:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue fell 4.50 percent to EUR 4.952 billion. Beiersdorf stock costs EUR 75.59 in trading on October 5, 2026 versus EUR 75.38.

Flatlay-Anordnung von Aktienzertifikat, ISIN-Karte, Cremetiegel und Hautpflegeutensilien — Flatlay mit Aktienzertifikat und Pflegeprodukten illustriert das Geschäft von Beiersdorf AG, ISIN DE0005200000, Illustration mit AI erstellt.

Beiersdorf stock (ISIN DE0005200000) was trading at EUR 75.59 at Lang & Schwarz on October 5, 2026 at 10:43 a.m. CEST, up 0.28 percent versus the prior close of EUR 75.38. On October 1, 2026, DZ Bank cut its fair value for Beiersdorf from EUR 77.00 to EUR 74.00 while keeping a Hold rating, as finanzen.net reported.

NIVEA weakness drives the debate

The valuation cut centers on the gap between Beiersdorf's strong Derma business and weaker core brands. DZ Bank analyst Thomas Maul described the recovery as slow in the October 1 outlook, while the October 27 quarterly report is the next major test cited in recent analyst coverage.

Jefferies had already reduced its target from EUR 76.00 to EUR 74.00 on September 28, 2026 and kept a Hold rating, citing inventory reductions in Western Europe, retail tensions and frozen Russian assets, according to finanzen.net. That makes the EUR 74.00 level a repeated point of caution in the latest research, even as Beiersdorf trades above it.

First-half figures show the split

Beiersdorf reported revenue of EUR 4.952 billion for the first half of 2026, down 4.50 percent from EUR 5.188 billion a year earlier. EBIT excluding special factors fell to EUR 768.0 million from EUR 836.0 million, taking the margin to 15.50 percent from 16.10 percent, while net income reached EUR 558.0 million versus EUR 561.0 million, according to Merca2.0.

The portfolio split is sharper than the group totals suggest. NIVEA and Labello sales fell 6.80 percent organically to EUR 2.703 billion in the first half of 2026, while Derma sales increased 7.80 percent organically to EUR 837.0 million. Beiersdorf also plans EUR 100.0 million of additional consumer-facing investment in the second half of 2026, adding pressure to near-term profitability.

Stock valuation and the next test

Beiersdorf's investor-relations page lists the half-year results dated August 3, 2026 and identifies October 27, 2026 as the date for the next quarterly report, according to Beiersdorf. The market is therefore weighing a near-term margin reset against the prospect of a NIVEA recovery plan running for 18 months.

Beiersdorf stock holds above EUR 75

Beiersdorf stock was trading at EUR 75.59 at Lang & Schwarz on October 5, 2026 at 10:43 a.m. CEST, up 0.28 percent versus the EUR 75.38 prior close of October 2, 2026. Its market capitalization was EUR 16.5 billion as of October 5, 2026, while the 52-week range stood at EUR 67.08 to EUR 110.20.

The further course of trading is shown by the continuously updated real-time quote of Beiersdorf stock.